Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 1 1

Status

Recruiting 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 163Thoracic 7Gastrointestinal 7Breast 7Gynecologic 5CNS 5Head & Neck 3Dermatologic 3Sarcoma 2Plasma cell 2Other hematologic neoplasm 2NET 2Endocrine 2Other 1Lymphoid 1

Conditions

Neuroendocrine Tumors 15Thyroid Neoplasms 10Thyroid Cancer, Papillary 10Adenocarcinoma, Follicular 9Paraganglioma 4Adrenocortical Carcinoma 4Pheochromocytoma 3Gastro-enteropancreatic neuroendocrine tumor 3Cholangiocarcinoma 3Carcinoma, Transitional Cell 3Brain Neoplasms 3Uterine Cervical Neoplasms 2Urinary Bladder Neoplasms 2Testicular Neoplasms 2Somatostatinoma 2Prostatic Neoplasms 2Pancreatic Neoplasms 2Neuroblastoma 2Neoplasm Metastasis 2Multiple Endocrine Neoplasia Type 1 2Lung Neoplasms 2Carcinoma, Hepatocellular 2Breast Neoplasms 2Adrenal Gland Neoplasms 2Adenoma, Islet Cell 2von Hippel-Lindau Disease 1Vulvar Neoplasms 1Vaginal Neoplasms 1Uveal Melanoma 1Uterine Neoplasms 1

Interventions

atezolizumab 2Trastuzumab 2Magnetic Resonance Spectroscopy 2vandetanib 1tivozanib 1tipifarnib 1temsirolimus 1romidepsin 1pembrolizumab 1pasireotide 1methyl hydroxyethyl cellulose 1gadoteridol 1gadoterate meglumine 1gadolinium ethoxybenzyl DTPA 1gadodiamide 1gadobutrol 1gadobenic acid 1entinostat 1Walking 1Vinorelbine 1Suramin 1Standard of Care 1Specimen Handling 1Sirolimus 1Ritonavir 1Respiratory Therapy 1Radiotherapy 1Quality of Life 1Patient Reported Outcome Measures 1Paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Prostatic Neoplasms × Magnetic Resonance Spectroscopy × Endocrine × Clear all
NCT06788886 2025-12-30

Breathing Practice for Brain and Mental Health in Cancer and Neurodegenerative Diseases

Mayo Clinic

Phase NA Recruiting
147 enrolled
CNSEndocrineGenitourinaryNET

Brain Neoplasms, Multiple Sclerosis, Prostatic Neoplasms, Neuroendocrine Tumors

NCT07118176 2025-08-12

Determining the Biodistribution of an Imaging Tracer (68Ga-FAPi-46) in Patients With Solid Tumors or Hematologic Cancers

Jonsson Comprehensive Cancer Center

Phase 1 Recruiting
30 enrolled
BreastCNSEndocrineGastrointestinalGenitourinaryGynecologicHead & NeckNETSarcomaThoracic

Adrenal Gland Neoplasms, Anus Neoplasms, Urinary Bladder Neoplasms, Brain Neoplasms, Breast Neoplasms, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Carcinoma, Hepatocellular, Lung Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Penile Neoplasms, Prostatic Neoplasms, Salivary Gland Neoplasms, Sarcoma, Stomach Neoplasms, Testicular Neoplasms, Thyroid Neoplasms, Uterine Neoplasms, Vaginal Neoplasms, Colorectal Neoplasms, Carcinoma, Medullary, Cholangiocarcinoma, Neuroendocrine Tumors, Solitary Fibrous Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡